tiprankstipranks
Advertisement
Advertisement

HK:6938 Stock Latest News

Suzhou Ribo forecasts sharp revenue surge on siRNA licensing deals
Company AnnouncementsSuzhou Ribo forecasts sharp revenue surge on siRNA licensing deals
10d ago
6938
Suzhou Ribo Wins EMA Nod for Phase 2b Trial of FXI siRNA Anticoagulant
PremiumCompany Announcements
Suzhou Ribo Wins EMA Nod for Phase 2b Trial of FXI siRNA Anticoagulant
11d ago
6938
Suzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CAD
PremiumCompany Announcements
Suzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CAD
17d ago
6938
Suzhou Ribo Life Science Signals Confidence With HK$9.3 Million Share Buyback
PremiumCompany Announcements
Suzhou Ribo Life Science Signals Confidence With HK$9.3 Million Share Buyback
26d ago
6938
Suzhou Ribo Executive Boosts Stake in H Shares, Signalling Confidence in Growth Prospects
PremiumCompany Announcements
Suzhou Ribo Executive Boosts Stake in H Shares, Signalling Confidence in Growth Prospects
29d ago
6938
Suzhou Ribo Executive Director Increases Stake in H Shares
PremiumCompany AnnouncementsSuzhou Ribo Executive Director Increases Stake in H Shares
1M ago
6938
Suzhou Ribo Hits First Milestone in Madrigal siRNA Liver Disease Partnership
Premium
Company Announcements
Suzhou Ribo Hits First Milestone in Madrigal siRNA Liver Disease Partnership
1M ago
6938
Suzhou Ribo Moves to Fully Align Azemidite Stake with RMB70 Million Buyout
Premium
Company Announcements
Suzhou Ribo Moves to Fully Align Azemidite Stake with RMB70 Million Buyout
1M ago
6938
Suzhou Ribo Life Science Unveils Dual H-Share Purchase and Buyback Plan
PremiumCompany Announcements
Suzhou Ribo Life Science Unveils Dual H-Share Purchase and Buyback Plan
2M ago
6938
Suzhou Ribo Shareholders Clear All Resolutions at 2025 AGM
PremiumCompany Announcements
Suzhou Ribo Shareholders Clear All Resolutions at 2025 AGM
2M ago
6938
Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing
PremiumCompany Announcements
Suzhou Ribo Advances CAD siRNA Drug With EMA Phase II Filing
2M ago
6938
Suzhou Ribo Reschedules AGM and Adjusts H Share Register Closure
PremiumCompany Announcements
Suzhou Ribo Reschedules AGM and Adjusts H Share Register Closure
3M ago
6938
Suzhou Ribo Life Science Sets AGM to Vote on Governance, Share Incentives and New Issuance Mandate
PremiumCompany AnnouncementsSuzhou Ribo Life Science Sets AGM to Vote on Governance, Share Incentives and New Issuance Mandate
3M ago
6938
Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial
Premium
Company Announcements
Suzhou Ribo Advances Vortosiran With EMA Filing for Phase 2b VTE Trial
3M ago
6938
Suzhou Ribo Hits Third Milestone in Boehringer Ingelheim Liver Disease Collaboration
Premium
Company Announcements
Suzhou Ribo Hits Third Milestone in Boehringer Ingelheim Liver Disease Collaboration
3M ago
6938
Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing
PremiumCompany Announcements
Suzhou Ribo Advances Lead siRNA Anticoagulant With EMA Phase 2b Filing
4M ago
6938
Suzhou Ribo Life Science Plans New H-Share Incentive Schemes for Staff and Partners
PremiumCompany Announcements
Suzhou Ribo Life Science Plans New H-Share Incentive Schemes for Staff and Partners
5M ago
6938
Suzhou Ribo Moves to Streamline Governance and Scrap Supervisory Committee
PremiumCompany Announcements
Suzhou Ribo Moves to Streamline Governance and Scrap Supervisory Committee
5M ago
6938
Suzhou Ribo Life Science Widens Loss as Listing Costs Rise Despite Revenue Growth
PremiumCompany Announcements
Suzhou Ribo Life Science Widens Loss as Listing Costs Rise Despite Revenue Growth
5M ago
6938
Suzhou Ribo Life Science Boosts Leadership With New CMO and CBO Appointments
PremiumCompany AnnouncementsSuzhou Ribo Life Science Boosts Leadership With New CMO and CBO Appointments
5M ago
6938
Suzhou Ribo Schedules Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
Premium
Company Announcements
Suzhou Ribo Schedules Board Meeting to Approve 2025 Annual Results and Consider Final Dividend
5M ago
6938
Suzhou Ribo Advances PCSK9 siRNA Drug RBD7022 Into Phase III Trial in China
Premium
Company Announcements
Suzhou Ribo Advances PCSK9 siRNA Drug RBD7022 Into Phase III Trial in China
5M ago
6938

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >